Phase III QMS
As a clinical programme progresses into Phase III, the complexity of the organisation, clinical activities, external partnerships and regulatory expectations typically increases. The OZQA Phase III QMS package is designed to help biotech and pharmaceutical companies mature their existing quality system for late stage clinical development, increased regulatory scrutiny and the transition towards commercialisation.
WHAT YOU NEED
From clinical QMS to mature quality organisation.
By Phase III, clinical programmes are typically larger and more complex. More activities may be outsourced, manufacturing and supply chains become increasingly important, regulatory interactions increase and the organisation needs greater visibility of quality performance across its operations and partners. The OZQA Phase III QMS builds on the quality foundation established during Preclinical and Phase I/II development and introduces additional processes for late stage quality governance and oversight.
Already operate an appropriate QMS?
Add the Phase III processes needed to support late stage clinical development.
Ideal for:
-
Sponsors with an established GCP QMS
-
Organisations preparing for increased regulatory scrutiny or commercialisation
Add the clinical and GCP processes required to evolve your existing quality system into a late clinical Sponsor QMS.
Starting from scratch?
Build a complete clinical Sponsor QMS with OZQA.
Ideal for:
-
For organisations entering late stage development without a sufficiently mature quality framework.
Combine the appropriate modules with the Phase III documentation to establish an integrated QMS for your organisation.
THE PHASE I/II QMS MODULES
A QMS designed for Phase III development
The Phase III package is an upgrade module for organisations that already operate an appropriate clinical Sponsor QMS. It introduces additional processes relevant to organisations preparing for late stage development, regulatory inspections and eventual transition towards a marketed product.
If your organisation does not already have the necessary foundational processes, OZQA can also provide a complete QMS solution combining the relevant earlier stage modules.
The documentation package for phase III includes:
Defines the structure, scope and principles of your Quality Management System.
As your organisation grows, quality management should provide visibility into how the QMS is actually performing.
Establishes expectations for accurate, complete, consistent and traceable documentation and appropriate handling of source and raw data.
The process establishes a risk based approach to assessing and overseeing external organisations performing activities on behalf of the sponsor.
Defines the responsibilities of operational and quality functions and establishes appropriate mechanisms for review, escalation and quality decision making.
Defines the respective responsibilities of operational and the Quality Unit and how quality related decisions, oversight, escalation etc. activities are managed.
SPONSOR BIOTECH COMPANIES
Strengthen inspection readiness.
By Phase III, regulatory inspection readiness should increasingly become part of normal quality operations rather than a project initiated shortly before an inspection. Your organisation should be able to demonstrate not only that procedures exist, but that they are implemented effectively.
This includes being able to show:
-
Clear roles and responsibilities
-
Appropriate personnel training
-
Controlled documentation and records
-
Effective CAPA and Change Control
-
Risk based quality management
-
Appropriate oversight of CROs, CMOs and other partners
-
Quality performance and trends
-
Traceability of important decisions
-
Effective follow up of quality issues
OZQA can support Phase III organisations with QMS reviews, gap assessments, inspection readiness activities and mock inspections in addition to the documentation package.
WHAT YOU NEED
Scale your quality system for late stage clinical development.
The OZQA Phase III QMS provides a practical quality management system designed specifically for early stage biotech and pharmaceutical companies. Start with the processes that matter today. Add the MAH and pharmacovigilance modules when your development programme progresses.
_edited.png)
DEVELOP ALONGSIDE YOUR PRODUCT
Your existing QMS remains the foundation
The Phase III QMS is not designed to replace the system you used during Phase I and Phase II. It builds on it.
The goal is not to create unnecessary complexity. It is to establish a QMS that reflects your actual responsibilities as a clinical trial sponsor.
Pharmaceuticals
Add commercial and MAH quality processes as your product approaches and enters the market.
This modular approach allows your QMS to develop alongside your organisation without implementing commercial processes years before they are needed.
Preclinical
Move from having procedures to operating them consistently. Strengthen oversight, documentation, training and Quality governance as clinical activities and external partnerships increase.
Phase I & Phase II
Move from having procedures to operating them consistently. Strengthen oversight, documentation, training and Quality governance as clinical activities and external partnerships increase.
Bring together the documentation needed to support product safety, ingredients, manufacturing, claims and regulatory compliance. Ensure regulatory, product and Quality documentation is aligned before commercial distribution begins.
EU PV
Quality does not end at approval. Maintain oversight, pharmacovigilance, supplier control, CAPA, audits and continuous improvement throughout the product lifecycle.
Phase III
Ensure Quality systems, governance and documentation are mature enough to support late stage development and the transition towards regulatory submission and commercial operations.
MAH
Prepare the organisation for the transition from development into marketed product responsibilities, including ongoing Quality oversight, pharmacovigilance and relevant commercial Quality processes.
BUILT TO WORK TOGETHER
Not just individual templates.
Our products are developed as parts of connected Quality processes. Procedures define how the process works and forms capture the required evidence, and related processes connect one document with the wider QMS.
WHY QMS
Use your existing eQMS or let us help you choose one.
The OZQA Phase III QMS is system independent. You are not required to purchase a specific software platform to use our documentation. The QMS can be implemented within an appropriate existing system or eQMS. If you are moving from a simpler preclinical setup into a dedicated electronic QMS, OZQA can also help define your requirements and assess suitable solutions. The system should support your quality processes and regulatory responsibilities – not dictate them.
GXP DEVELOPED STANDARDS
Built by life science QA professionals
OZQA combines practical quality and regulatory experience with ready to implement QMS documentation. Our approach is designed for organisations that need a compliant and scalable quality framework without building unnecessary complexity into their operations. Whether you are developing your first therapeutic candidate or preparing to move towards clinical development, we help you implement the level of quality management that is appropriate for where you are today.
 GMP |  GVP |
|---|---|
 GCP |  GDP |
FREQUENTLLY ASKED QUESTIONS
FAQ
Building a Quality Management System during preclinical development often raises practical questions. How much QMS do you actually need? Which SOPs should be implemented first? Do you need an electronic QMS? And what happens to the system when your first clinical trial approaches?
The right answer depends on your development stage, organisation, outsourced activities and regulatory roadmap. A preclinical QMS should therefore be proportionate to the activities you perform today, while providing a foundation that can grow with your organisation.